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S U M M A R Y
Objective: Atypical presentations of herpes simplex genitalis are becoming more frequent. The aim of this
study was to investigate the atypical clinical manifestations and treatment of this infection.
Methods: The charts of patients with herpes simplex genitalis who attended our clinics between January
2009 and December 2013 were reviewed retrospectively.
Results: Of 294 patients, 147 (50%) were male with a mean (standard deviation, SD) age of 48.3 (16.8)
years. An ulcerative lesion was the most common symptom (48.3%), followed by vesicle clusters (36.4%).
The mean duration of symptoms at ﬁrst visit was 6 days. Oral acyclovir was administered to 87.6% of
patients. Hypertrophic manifestations were observed in 4.8% (14/294) of patients; 50% (7/294) were
male, with a mean age of 44.5 (SD 9) years. All patients with hypertrophic manifestations were infected
with HIV. Hypertrophic manifestations had a mean duration of onset of 53.3 days. Acyclovir was
prescribed to 11 (78.6%) patients. The mean duration to cure was 40.9 days. Topical imiquimod was given
in six resistant cases (42.9%) as adjunctive therapy.
Conclusions: Atypical manifestations of herpes simplex genitalis require careful consideration because
their frequency is rising, particularly in patients with HIV infection. Although acyclovir is important in
their treatment, imiquimod provides an additional beneﬁt in resistant cases.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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Herpes simplex genitalis is a sexually transmitted infection
(STI), and is one of the most important problematic public health
issues worldwide. Globally, the incidence of herpes simplex
genitalis is about 23.6 million persons per year, and it has been
increasing, especially among patients with HIV infection.1
Moreover, herpes simplex genitalis is also a marker lesion for
new HIV cases and vice versa.2,3
Skin lesions from herpes simplex virus (HSV) infection,
particularly those consisting of unusual mucocutaneous wart-
like and/or ulcerative types, lasting longer than 1 month, are* Corresponding author. Tel.: +66 2 419 4333; fax: +66 2 411 5031.
E-mail address: charussrilee@gmail.com (C. Leeyaphan).
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license (http://creativecommons.org/licenses/by-nc-sa/4.0/).among the AIDS-deﬁning illnesses.4,5 Many atypical presenta-
tions, especially a hypertrophic pattern, most commonly seen in
HIV-positive or immunocompromised patients, have been ob-
served increasingly in clinical practice,5–7 resulting in difﬁculties in
diagnoses, increased drug resistance, and recurrence. Over the last
two decades, several cases of a peculiar clinical appearance –
hypertrophic herpes simplex genitalis – have been reported.8
However, these clinical manifestations have not been well studied in
terms of HIV-infected patients and non-HIV patients. These previous
case reports and case series are limited, as they did not compare
clinical characteristics between HIV-infected and non-HIV
patients.5–8
In Thailand, herpes simplex genitalis is one of the most
common STIs.9However, clinical characteristics of herpes simplex
genitalis in Thai patients are not well reported, and to our
knowledge there has been no published report describing atypicalciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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clinical presentation increasingly observed in clinical practice has
led to the use of novel treatment modalities such as immuno-
modulatory agents, and in particular, topical imiquimod cream as
an adjunctive therapy to the ﬁrst-line drug, acyclovir, in order to
achieve both curative and further preventive outcomes.8,10-30 The
successful use of topical imiquimod cream for the treatment of
atypical, mostly presumed acyclovir-resistant, hypertrophic
herpes simplex genitalis often seen in HIV-positive or immuno-
compromised patients has been reported.8,11–20,29,30
This study aimed to focus on atypical clinical manifestations of
herpes simplex genitalis and also to describe demographic data,
other clinical presentations, laboratory investigations, treatment,
recurrence, and associated complications. To the best of our
knowledge, this study is the largest published series of hypertro-
phic herpes simplex genitalis patients, as well as the largest
published series of genital herpes patients receiving imiquimod
treatment. Moreover, this study demonstrates the differences in
clinical manifestations of herpes simplex genitalis between HIV-
infected and non-HIV-infected groups.
2. Methods
2.1. Subjects
This was a retrospective chart review of patients diagnosed
with herpes simplex genitalis who attended two sexually
transmitted disease clinics, at the Department of Dermatology,
Siriraj Hospital and the Bamrasnaradura Infectious Disease
Institute, between January 2009 and December 2013. This study
was approved by the institutional review boards of the Faculty of
Medicine Siriraj Hospital and Bamrasnaradura Infectious Disease
Institute and was performed in compliance with the latest version
of the Declaration of Helsinki. Because this study involved a
retrospective chart review and patients remained anonymous,
informed consent was not obtained from the patients included.
Diagnoses were based mainly on clinical presentations and
physical examination. Laboratory investigations were applied in
some atypical cases to support diagnoses. Demographic data, HIV
status, clinical manifestations, laboratory investigations, treat-
ment regimens, history of recurrence, and complications were
collected. All medical records that fulﬁlled the diagnostic criteria
were collected. Incomplete medical records were excluded. Data
were then compared and analyzed between HIV-infected and non-
HIV-infected groups.Table 1
Characteristics of herpes simplex genitalis patients recruited in the study
Characteristics Total patients
(n = 294)
HIV
pa
Sex, male 147 (50%) 52
Age, years, mean (SD) 48.3 (16.8) 41
Symptoms
Group of vesicles 107 (36.4%) 12
Ulcerative 142 (48.3%) 56
Hypertrophic 14 (4.8%) 14
Other 31 (10.5%) 2
Dysuria 16 (5.4%) 1
Inguinal lymph node 4 (1.4%) 3
Duration of symptoms, days, mean (SD) 6 (27.0) 9
With complications 13 (4.4%) 7
Recurrence 86 (29.3%) 29
HIV, human immunodeﬁciency virus; OR, odds ratio; CI, conﬁdence interval; SD, stand
a Statistical signiﬁcance, p  0.05.
b p < 0.001, hypertrophic vs. group of vesicles.2.2. Statistical analysis
A Chi-square test was used to compare differences in
categorical data and an independent t-test was used for continuous
variables. A p-value of <0.05 was considered statistically signiﬁ-
cant. The odds ratio (OR) with 95% conﬁdence interval (CI) was also
calculated for each relevant variable. All analyses were performed
using SPSS for Windows version 18.0 software (SPSS Inc., Chicago,
IL, USA).
3. Results
Of 294 patients with herpes simplex genitalis included in this
study, diagnosed by clinical presentation and physical examina-
tion alone or with additional laboratory investigations, 50% (147/
294) were male with a mean (standard deviation, SD) age of 48.3
(16.8) years. The reported sexual risk behaviours were sexual
relationship without condom use (66.7%) and multiple sexual
partners (47.5%). An ulcerative lesion was the most common
presenting symptom (48.3%) and the mean duration of symptoms
at ﬁrst visit was 6 days. Sixty-nine (31.2%) patients presented with
a ﬁrst disease episode and 152 (68.8%) presented with a recurrent
episode. Only 33.7% of patients (n = 99) underwent a Tzanck smear
investigation, of whom 54.5% had a positive result. Of all the
patients, 15.6% were also investigated for HSV by direct
immunoﬂuorescence antibody testing, with 52.6% yielding a
positive result. Two hundred and ﬁfty-eight (87.6%) patients had
been treated with oral acyclovir. Complications such as secondary
bacterial infection were found in 4.4%, and recurrence in a 5-year
follow-up period was 29.3%.
Differences between the groups showed that the HIV-infected
group had signiﬁcantly more male patients. These patients were
also younger, had increased hypertrophic-type symptoms, longer
durations of symptoms, an increased complication rate, and a
higher likelihood of recurrence (p < 0.05) (Table 1).
Hypertrophic manifestations were noticed in 14 (4.8%) of the
294 patients, and they were all infected with HIV (Figure 1).
Compared with patients infected with typical HSV, patients infected
with the hypertrophic type were younger and had a higher incidence
of HIV infection, longer duration of symptoms, increased use of
imiquimod therapy, and a longer duration to cure (Table 2).
Hypertrophic patients who were non-responsive to acyclovir
were treated with imiquimod and this showed promising results.
One patient was administered imiquimod for prophylaxis of
recurrence.-infected
tients (n = 84)
Non-HIV-infected
patients (n = 210)
OR (95% CI); p-value
 (61.9%) 95 (45.2%) 2.0 (1.2–3.3); 0.010a
.9 (9.4) 50.8 (18.4) <0.001a
 (14.3%) 95 (45.5%) 66.6 (3.9–1133)b
 (66.7%) 86 (41.0%)
 (16.7%) 0 (0.0%)
 (2.4%) 29 (13.8%)
 (1.2%) 15 (7.1%) 0.046
 (3.6%) 1 (0.5%) -
 (45.9) 5 (9.2) <0.001a
 (8.3%) 6 (2.9%) 4.4 (1.4–13.8) 0.012a
 (34.5%) 57 (27.2%) 2.6 (1.4–4.9) 0.003a
ard deviation.
Figure 1. Clinical images of (A) the typical form, and (B) the hypertrophic form of herpes simplex genitalis.
Table 2
Clinical features of hypertrophic herpes simplex genitalis compared with typical herpes genitalis
Characteristics Hypertrophic herpes
simplex genitalis
(n = 14)
Typical herpes
simplex genitalis
(n = 280)
OR (95% CI); p-value
Sex, male 7 (50%) 140 (50%) 0.128
Age, years, mean (SD) 44.5 (9) 48.5 (17) 0.012a
With HIV infection 14 (100%) 70 (25%) <0.001a
Mean CD4+ count, cells/mm3 317.7 358.0 0.297
Onset duration, days, mean (SD) 53.3 (45.4) 12.1 (24.0) <0.001a
Acyclovir treatment 11 (78.6%) 247 (88.2%) 0.018a
Topical imiquimod 6 (42.9%) 2 (0.7%) 0.001a
Duration to cure, days, mean (SD) 40.9 (33.8) 12.4 (9.5) 0.001a
Recurrence 3 (21.4%) 209 (74.6%) 0.482
OR, odds ratio; CI, conﬁdence interval; SD, standard deviation; HIV, human immunodeﬁciency virus.
a Statistical signiﬁcance, p  0.05.
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Herpes simplex genitalis is one of the most common STIs in
Thailand and its incidence has been increasing worldwide,
especially in patients with HIV co-infection.1–3 The current study
showed the ulcerative lesion to be the most encountered
presenting symptom (48.3% overall, 66.7% in the HIV-positive
group), whereas groups of vesicles was the second most common
presentation. Most patients presented with a recurrent infection.
Treatment with thymidine kinase-dependent antivirals such as
acyclovir is still the mainstay of prescribed therapy. For the
treatment of recurrent episodes, thymidine kinase-dependent
antivirals have been shown to reduce the time of healing, time of
cessation of viral shedding, and duration of symptoms. An effective
episodic treatment should start within 1 day of lesion onset or
during the prodromal symptoms. However, the current study
showed that the mean duration of symptoms at ﬁrst visit was
6 days, which is quite delayed. This might contribute to more
severe presenting symptoms, such as the ulcerative type, and
reduced effectiveness of episodic treatment. Moreover, previous
studies have shown that many patients, even those with mild or
unrecognized infections, still shed virus intermittently. The US
Centers for Disease Control and Prevention 2010 treatment
guidelines for genital HSV infections suggest that we should focusbeyond the treatment of ulcers and emphasize suppressive therapy
to reduce recurrence and prevent transmission.10
Hypertrophic lesions are often seen in immunocompromised
patients, including HIV-infected patients (Table 3).5–7,11–19 A
review of the literature dating back to the ﬁrst case report in
1996,28 showed that there have been no published reports
describing atypical HSV manifestations in Thailand.5–8 In the
current study, hypertrophic lesions were only observed in HIV-
infected patients independent of CD4 cell counts, which indicates
that HIV infection might be involved in the pathogenesis of
hypertrophic herpes simplex infections. Previous studies have
addressed hypertrophic types as a dermatological manifestation of
immune reconstitution inﬂammatory syndrome (IRIS) or immune
restoration disease.4,6,8 This atypical manifestation underlines
the difﬁculties in diagnoses and in deciding on treatments. In
addition, the current study revealed that younger age was
signiﬁcantly associated with atypical manifestations. The mean
duration of this atypical symptom was 53.3 days, which was
signiﬁcantly longer than those of a typical infection. In addition,
hypertrophic lesions had a longer mean duration to cure when
compared with typical lesions.
Although acyclovir-resistant HSV is prevalent, especially
among those with the hypertrophic type, and complementary
alternative therapy is often initiated,11–19 acyclovir remains the
Table 3
Literature review of hypertrophic herpes simplex genitalis
Author (year) Age and
gender
HIV status CD4+ T-cells,
cells/mm3
Site Lesion
size, cm
Treatment Follow-up outcome
Strehl et al.
(2012)8
44 F Positive (HAART) 403 Vulva 2, 2.8 (1) Surgery and ACV,
followed by VCV
(2) Imiquimod
(1) Recurrence after 5 months
(2) Recurrence after 4 months
Lestre et al.
(2011)29
49 F Positive 197 Peri-anal
region
4 (1) ACV
(2) Followed by VCV
(3) Topical imiquimod +
VCV
(1) Loss of response after
2 months
(2) No response
(3) Resolution of lesion after
10 weeks of treatment
Barbosa et al.
(2011)30
42 M Positive 150 Scrotum 10 (1) Surgery and IV ACV
10 mg/kg 3 times a day for
10 days
(2) Topical imiquimod +
VCV
(1) Partially improved
(2) Resolution of lesion after
3 months of treatment and no
sign of relapse
45 M Positive 315 Genital area
(not speciﬁed)
12 (1) IV VCV for 10 days
(2) ACV 400 mg every 8 h
(3) Topical imiquimod +
ACV
(1) Partially improved
(2) No response
(3) Resolution of lesion after
1 month and no sign of relapse
after 6 months follow-up
Cury et al.
(2010)20
63 M Positive (HAART) 314 Peri-anal region 3.0 (1) Surgery
(2) IV cidofovir
(3) Thalidomide
(4) Repeat surgery and
topical imiquimod
(1) Recurrence after 2 months
(2) No response
(3) No response
(4) N/A
Mosunjac et al.
(2009)4
51 F Positive (HAART) 142 Vulva 2.0 Surgery and ACV N/A
41 M Positive (HAART) 185 Scrotum 5.0 Surgery and ACV + VCV+
foscarnet
N/A
40 M Positive (HAART) 362 Perineum 7.0 Surgery and ACV + VCV+
foscarnet
N/A
51 F Positive 108 Vulva, gluteal 3.6 Surgery and ACV N/A
40 F Positive 135 Anus 2.7 Surgery and ACV N/A
53 M Positive 156 Peri-anal and
scrotum
6.8 Surgery and ACV N/A
41 M Positive (HAART) 124 Perineum 3.0 Surgery and ACV N/A
37 M Positive (HAART) 14 Peri-anal 9.0 Surgery and ACV N/A
40 M Positive 306 Scrotum 1.9 Surgery and ACV N/A
Maharaj et al.
(2009)21
38 F Positive (HAART) 188 Vulva 8 (1) ACV, VCV
(2) IV ACV
(1) No response
(2) Moderate response
Simonsen et al.
(2008)22
39 M Positive (HAART) 400 Peri-anal 3 (1) ACV
(2) Surgery and ACV
(1) No response
(2) Resolution of lesion
Yudin and Kaul
(2008)15
35 F Positive (HAART) 156 Left labia 3 (1) ACV
(2) VCV
(3) IV foscarnet
(4) Topical imiquimod
(1) No response
(2) No response
(3) Temporary remission
(4) Resolution of lesion
Hanjani et al.
(2007)23
69 F Negative N/A Left labia
majora
7 Surgery Resolution (3 months)
Holmes et al.
(2007)5
30 M Positive (HAART) >200 Peri-anal
region
10 (1) Oral and IV VCV
(2) Foscarnet
(3) IV cidofovir
(4) Thalidomide
(1) No response
(2) No response
(3) No response
(4) Resolution of lesion
Nadal et al.
(2005)24
41 M Positive (HAART) 73 Peri-anal
region
3–12 (1) Surgery
(2) Oral and topical ACV
(3) Repeat surgery
(4) Oral and topical ICV,
interferon B
(1) Recurrence after 12 months
(2) No response
(3) Recurrence after 2 months
(4) Resolution of lesion
46 M Positive (HAART) 370 Peri-anal
region
3–12 Surgery Resolution of lesion
49 M Positive (HAART) 186 Peri-anal
region
3–12 (1) Surgery
(2) Oral and topical ACV
(3) Repeat surgery
(1) Recurrence after 10 months
(2) No response
(3) Resolution of lesion
42 M Positive (HAART) 251 Peri-anal
region
3–12 (1) Surgery
(2) Oral and topical ACV
(1) Recurrence after 3 months
(2) Resolution of lesion
54 F Positive (HAART) 116 Peri-anal
region
3–12 Surgery Resolution of lesion
Gubinelli et al.
(2003)25
46 M Positive (HAART) 500 Intergluteal
cleft
N/A (1) Oral ACV
(2) Oral VCV
(1) No response
(2) Resolution of lesion
Carrasco et al.
(2002)26
28 M Positive (HAART) 346 Scrotum 10 (1) Oral ACV
(2) Oral VCV
(1) No response
(2) Resolution of lesion
Samaratunga
et al. (2001)27
46 M Positive (HAART) 400 Peri-anal 5 Surgery Resolution of lesion
Tong and
Mutasim (1996)28
32 M Positive (HAART) N/A Intergluteal
cleft
13 ACV Resolution of lesion
This study
Leeyaphan
et al. (2014)
35 M Positive (HAART) 356 Peri-anal
region
N/A ACV, topical imiquimod Resolution after 21 days
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Table 4
Summary of case reports of imiquimod for the treatment of acyclovir-resistant herpes simplex genitalis
Author (year) Age and
gender
Medical
condition
HSV type Imiquimod
regimen
Time to healing Follow-up Recurrence Prophylaxis
Strehl et al.
(2012)8
44 F HIV HSV-2 N/A 4 months 2 months 3 times Famvir
Lestre et al.
(2011)29
49 F HIV HSV-2 3/week for 2 weeks
then 5 days/week
for 8 weeks
10 weeks 2 months N/A Valacyclovir
1 g/day
Barbosa et al.
(2011)30
42 M HIV N/A N/A 3 months Yes, time
not noted
No No
45 M HIV N/A 3/week 1 month 6 months No Acyclovir
Perkins et al.
(2011)11
45 F HIV HSV-2 3/week then daily 4 weeks 12 months 4 times Acyclovir
78 M B-cell
lymphoma
HSV-2 Alternate days 6 weeks 4 months Persisting
ulceration
Imiquimod
(alternate days)
42 M HIV N/A 3/weeks 3 weeks Yes time
not noted
2 times Acyclovir
Cury et al.
(2010)20
63 M HIV HSV-2 N/A N/A N/A N/A Valacyclovir
Bangsgaard and
Skov (2008)19
79 F Lymphatic
leukaemia
HSV-2 3/week then daily 14 weeks None N/A N/A
Lautenschlager
et al. (2008)12
46 M HIV HSV-2 3/week 5 weeks Yes, time
not noted
Several N/A
Yudin and Kaul
(2008)15
35 F HIV HSV-2 3/week 8 weeks 21 months None Valacyclovir,
imiquimod
Abbo et al.
(2007)16
42 M HIV HSV-2 3/week 2 weeks None N/A N/A
Brummit
(2006)18
72 F Rheumatoid
arthritis
(methotrexate)
HSV-2 3/week 10 weeks 9 months One N/A
Martinez et al.
(2006)14
37 M HIV HSV-2 3/week (stopped
after 2 weeks)
4 weeks 12 months None No
31 M Lymphocytic
leukaemia
HSV-1 4  daily 4 weeks
then daily for 3 months
4 weeks 10 months None Valacyclovir
Danielson
et al. (2002)17
28 M HIV HSV-1 N/A 10 weeks 20 months None Famciclovir
Gilbert et al.
(2001)13
34 M HIV HSV-2 3/week 1 week 1 month None N/A
This study
Leeyaphan
et al. (2014)
35 M HIV N/A 3/week 21 days 2 months No No
55 M HIV N/A 3/week 79 days 1 month No No
35 F HIV N/A 3/week 70 days 3 months No Yes, imiquimod
2/week
37 F HIV N/A 3/week 30 days 2 months No No
40 F HIV N/A 3/week 28 days 27 months No No
50 F HIV N/A 3/week 60 days 48 months Yes, at 12 months No
HSV, herpes simplex virus; F, female; M, male; HIV, human immunodeﬁciency virus; N/A = Not applicable.
Table 3 (Continued )
Author (year) Age and
gender
HIV status CD4+ T-cells,
cells/mm3
Site Lesion
size, cm
Treatment Follow-up outcome
55 M Positive (HAART) 47 Peri-anal
region
N/A Topical imiquimod Resolution after 79 days
35 F Positive (HAART) 330 Labia N/A ACV, AMC, Pred, topical
imiquimod
Resolution after 70 days
37 F Positive (HAART) 1009 Peri-anal
region
N/A Topical imiquimod, AMC Resolution after 30 days
40 F Positive (HAART) 284 Labia, peri-anal
region
N/A ACV, topical imiquimod Resolution after 40 days
50 F Positive (HAART) 171 Labia majora N/A ACV, Pred, topical imiquimod Resolution after 60 days and
recurrence at 12 months
follow-up
43 M Positive (HAART) 421 Penis N/A ACV Recurrence after 300 days
52 M Positive (HAART) 398 Scrotum N/A ACV, Pred, AMC Resolution after 20 days
52 M Positive (HAART) 146 Genitalia N/A ACV Recurrence after 150 days
58 M Positive (HAART) 98 Buttock N/A Fucidin ointment Loss to follow-up
44 M Positive (HAART) 5 Penis N/A ACV Loss to follow-up
33 F Positive (HAART) 355 Labia N/A ACV, AMC Resolution of lesion
35 F Positive N/A Labia majora N/A ACV Loss to follow-up
53 F Positive (HAART) 510 Labia N/A ACV Loss to follow-up
HIV, human immunodeﬁciency virus; F, female; M, male; HAART, highly active antiretroviral therapy; ACV, acyclovir; VCV, valacyclovir; IV, intravenous; N/A = not applicable;
AMC, co-amoxiclav; Pred, prednisolone.
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an additional therapy to acyclovir, is effective for the treatment of
hypertrophic herpes simplex infection. Imiquimod, an imidazo-
quinoline, is an immunomodulatory drug that signals through toll-
like receptor 7 to stimulate cell-mediated immune responses.11–19
These immunomodulatory effects result in the resolution of viral
lesions without the potential for the development of drug
resistance, because imiquimod exerts its action through host
immunity rather than as a direct antiviral agent.11–19
A literature review dating back to the ﬁrst case report of
imiquimod prescription for the treatment of presumed acyclovir-
resistant herpes simplex genitalis in 2001,13 demonstrated a
successful outcome when using topical imiquimod cream on
hypertrophic herpes simplex genitalis, which is often seen in HIV-
positive or immunocompromised patients (Table 4).
For hypertrophic herpes simplex infection, imiquimod treat-
ment could have a beneﬁcial clinical outcome, as shown in this
study and in previous case studies (Table 4). Therefore, topical
imiquimod shows promising results for the treatment of hyper-
trophic herpes simplex infection. To the best of our knowledge, the
current study is the largest published series of hypertrophic herpes
simplex genitalis lesions that were also treated with adjunctive
imiquimod. However, this was a retrospective chart review, and
the main study limitation is the lack of information from
incomplete medical records.
Herpes simplex genitalis is a marker lesion for new HIV cases.
Atypical manifestations, especially the hypertrophic type, should
be considered with caution because they are not uncommon. Such
manifestations account for 4.8% of all patients with herpes simplex
genitalis treated in our clinics, and they are particularly noted in
those with HIV infection. Moreover, unfamiliar manifestations in
atypical cases can make the diagnosis of herpes infection difﬁcult.
Acyclovir still plays a major role in the treatment regimen for
herpes simplex genitalis; however, in atypical cases, this study
showed that imiquimod provides an additional beneﬁt.
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